No. 1 is K-US500X-C(A) +22.61%
Bualuang US Alpha RMF
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
B-USALPHARMF invests through the master fund JPMorgan Funds - US Growth Fund 99.24%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per JPMorgan fact sheet · Country inferred from the name of a single-country fund
Over the past year it was in the bottom 25% of its group; over 3 years it returned +13.49% per year (Below half the group)
No. 1 is K-US500X-C(A) +22.61%
Each bar is one fund in the AIMC US Equity group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| −0.06% | −2.22% | −2.24% | −5.99% | +1.93% | +0.67% | −5.21% | +46.17% | +20.91% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −31.26% Previous peak 28 Dec 2021 (NAV 10.1863) → Trough 5 Jan 2023 (NAV 7.0020) · Back to the previous peak on 23 Feb 2024, after 1 year 1 month
Currently −7.34% from the peak NAV of 13.0483 (6 Oct 2026)
Over 3 years, B-USALPHARMF returned 0.75 per unit of volatility, ranking 25 of 44 funds · The highest is K-US500X-A(A) (1.13)
กองทุนมีนโยบายลงทุนในต่างประเทศ โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน โดยจะเน้นลงทุนในหน่วยลงทุนของ JPMorgan Funds - US Growth Fund (กองทุนหลัก) ชนิดหน่วยลงทุน JPM US Growth I (acc) - USD เพียงกองทุนเดียว เฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80… Its largest holdings are JPMorgan Funds - US Growth Fund 99.24% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 2 Dec 2021, its NAV has fallen as much as −31.26% from its peak.
Actual total expense ratio (TER) 1.46% a year, against a ceiling of 3.48%. Management fee 1.34%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
B-USALPHARMF is a retirement mutual fund (RMF). You can buy up to 30% of your assessable income, capped at 500,000 THB a year together with other retirement funds. You must hold it for at least 5 years and can sell only once you turn 55. Check the latest conditions with the Revenue Department before investing
Hedged at the manager's discretion. As of 30 Sep 2026, 44.60% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Processors behind chatbots and cloud services, as well as gaming graphics cards
Parent company of Google, owner of YouTube, Android, Gmail and Google Cloud
Maker of iPhone, Mac, iPad and Apple Watch, with services such as App Store and iCloud
Designs networking chips and custom AI chips for tech companies, plus VMware software
A chip design company behind Ryzen processors, Radeon graphics cards and chips for AI data centres
Owner of Windows, Microsoft 365, the Azure cloud, Xbox consoles and LinkedIn
Diabetes and weight-loss drugs
Owner of Facebook, Instagram and WhatsApp, as well as smart glasses and AI technology
Makes DRAM and NAND memory chips, as well as HBM memory for AI chips
Based on the master fund's share of this fund's value (99.24% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from JPMorgan · Illustrations are for explanation only, not individual stock recommendations
No. 1 is K-US500X-C(A) +26.32% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −2.6 | −3.8 | −3.9 | +10.3 | +6.9 | +0.1 | −7.7 | +3.0 | +4.9 | −5.2 | −0.4 | · | −0.1* |
| 2025 | +2.8 | −5.0 | −8.2 | −0.2 | +7.3 | +5.5 | +3.9 | −0.9 | +5.3 | +3.3 | −3.9 | −1.3 | +7.6 |
| 2024 | +6.0 | +7.2 | +2.9 | −2.8 | +1.4 | +7.6 | −6.2 | +0.4 | −1.3 | +3.3 | +5.7 | −0.8 | +25.0 |
| 2023 | +2.4 | +1.9 | +2.5 | −0.1 | +6.1 | +6.4 | +1.5 | −0.4 | −3.6 | −4.8 | +9.8 | +2.9 | +26.4 |
| 2022 | −11.2 | −4.8 | +6.1 | −8.3 | −4.5 | −7.1 | +7.9 | +1.3 | −6.3 | +4.6 | −4.5 | −5.4 | −29.4 |